Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
First evidence of significant clinical activity of PD1 inhibition in metastatic prostate cancer

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.10.16
Views: 2087

Dr Julie Graff - Knight Cancer Institute, Oregon Health & Science University, Portland, USA

Dr Graff speaks with ecancertv at ESMO 2016 about her research, finding the first significant response of men with metastatic castration-resistant prostate cancer to PD-1 targetted therapy.

She describes how this challenges prior results of prostate cancer as a 'cold tumour', resistant to immunotherapy, and opens the way to new treatment pathways for men who have few therapeutic options.

Dr Graff also considers the positioning of PD-1 modulation as a front line therapy, as discussed by Dr Arjun Balar here.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation